Key result
BGP-15 attenuates imatinib-induced cardiac inflammation by suppressing cytokines and boosting antioxidant defenses.
Why the study?
BGP-15 exerts cardioprotective effects, but the mechanisms underlying its effects on imatinib-induced cardiac inflammation remain unclear.
Does BGP-15 prevent imatinib-induced cardiac inflammation in an animal model?
Does BGP-15 prevent imatinib-induced cardiac inflammation in an animal model?
p-value: p=<0.05
BGP-15 demonstrates potential as a cardioprotective adjunct against tyrosine kinase inhibitor-induced cardiotoxicity by mitigating PARP-1-mediated inflammatory pathways.
BGP-15, a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor exerts cardioprotective effects; however, the underlying mechanisms remain unclear. Therefore, our study aimed to investigate the effects of BGP-15 on the imatinib (Imtb)-induced cardiac inflammation at the biochemical level. Male rats were divided to control, Imtb-treated (60 mg/kg/day for 14 days), and Imtb + BGP-15-treated animals. In this group Imtb was co-administered with BGP-15 at the dose of 10 mg/kg/day. At the end of the experiment, nuclear factor-kappa B/p65 (NF-κB/p65), nuclear transcription factor erythroid-2 related factor (Nrf2), heme oxygenase-1 (HO-1), high mobility group box 1 (HMGB1), and myeloperoxidase (MPO) were measured by Western blot. Chemokine and interleukins (ILs) were determined by Legendplex. Additionally, cardiac specific changes were visualized by immunohistochemistry. We demonstrated that Imtb increased NF-κB/p65, IL-6, IL-1β, IL-18, MCP-1, HMGB1, as well as the expression and activity of MPO. Conversely, the expressions of antioxidant Nrf2 and HO-1 were decreased. Administration of BGP-15 effectively mitigated these inflammatory alterations by significantly reducing pro-inflammatory cytokines and MPO activity, while simultaneously restoring and enhancing the levels of Nrf2 and HO-1, thereby promoting antioxidant defenses. The immunohistochemical staining further supported these biochemical changes. Our study provides new and comprehensive biochemical insight for managing Imtb-induced inflammatory responses via BGP-15-induced PARP1 inhibition.
No takes yet. Share an insight, caveat, or question.
Szabó et al. (2025) studied Imatinib-induced cardiac inflammation (n=33). BGP-15 vs. Imatinib alone was evaluated on Cardiac inflammatory and antioxidant biomarkers (PARP1, NF-κB/p65, Nrf2, HO-1, HMGB1, MPO, cytokines) (p=<0.05). Administration of BGP-15 effectively mitigated imatinib-induced inflammatory alterations by significantly reducing pro-inflammatory cytokines and MPO activity while enhancing antioxidant defenses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: